Approval · Notice of Compliance 30188 · 2023
APO-POMALIDOMIDE: Notice of Compliance 30188
Issued February 22, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30188
- Date
- February 22, 2023
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- POMALYST (Celgene Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-POMALIDOMIDE | 02520427 | Marketed |
| APO-POMALIDOMIDE | 02520435 | Marketed |
| APO-POMALIDOMIDE | 02520443 | Marketed |
| APO-POMALIDOMIDE | 02520451 | Marketed |
Medicinal ingredients
- POMALIDOMIDE 1 MG per CAP
- POMALIDOMIDE 2 MG per CAP
- POMALIDOMIDE 3 MG per CAP
- POMALIDOMIDE 4 MG per CAP